Additional Information

Description

Ondansetron Orally Disintegrating Tablets, USP, 8 mg, are a pharmaceutical formulation designed to manage nausea and vomiting associated with various medical conditions. These tablets contain ondansetron hydrochloride as the active ingredient, a selective serotonin 5-HT3 receptor antagonist that inhibits the activation of vomiting pathways in the brain. They are commonly prescribed for patients undergoing chemotherapy, radiotherapy, or postoperative recovery, where nausea is a prevalent side effect.

The orally disintegrating form is uniquely suited for patients who may have difficulty swallowing traditional tablets. Upon placement on the tongue, the tablet rapidly dissolves without requiring water, making administration convenient and effective, especially in cases of severe nausea. The formulation ensures prompt absorption, facilitating rapid onset of action.

Excipients in the formulation are carefully selected to support the disintegration process while ensuring stability and patient tolerability. These include flavoring agents to mask the bitter taste of the active ingredient and binding agents that maintain structural integrity until use. The tablets are individually packaged to preserve their quality and protect against environmental factors such as moisture.

Clinical studies demonstrate that ondansetron is well-tolerated with a favorable safety profile when used as directed. Side effects, such as headache, constipation, or dizziness, are generally mild and transient. Proper storage and adherence to the prescribed dosage enhance its effectiveness in controlling nausea, significantly improving the quality of life for patients undergoing intensive treatments.